<DOC>
	<DOCNO>NCT00134485</DOCNO>
	<brief_summary>The Torcetrapib project terminate December 2 , 2006 due safety finding . To evaluate efficacy safety torcetrapib/atorvastatin compare atorvastatin alone patient heterozygous familial hypercholesterolemia</brief_summary>
	<brief_title>Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia</brief_title>
	<detailed_description>For additional information please call : 1-800-718-1021</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis Heterozygous Familial Hypercholesterolemia At least 18 year age Women pregnant lactating , plan become pregnant . Subjects clinically indicate need statin ( HMGCoA reductase inhibitor ) therapy atorvastatin concomitant therapy know lipid alter effect LDLC HDLC include fibrates nicotinic acid ( high dos ) Subjects take drug know associate increase risk myositis combination HMGCoA reductase inhibitor Subjects medical condition laboratory abnormality could affect subject safety , preclude evaluation response , render unlikely subject would complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>